N. Schaap

发表

Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning

J. Sierra, M. Labopin, A. Nagler, 2022 .

The Aryl Hydrocarbon Receptor Antagonist StemRegenin1 Improves In Vitro Generation of Highly Functional Natural Killer Cells from CD34(+) Hematopoietic Stem and Progenitor Cells.

J. Jansen, J. Cany, F. Preijers, 2015, Stem cells and development.

Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia ‐ A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT

J. Delgado, N. Kröger, P. Dreger, 2017, Clinical lymphoma, myeloma & leukemia.

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.

G. Mufti, N. Kröger, S. Iacobelli, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy.

M. Kester, J. Jansen, L. Gattinoni, 2014, Blood.

Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

M. Netea, J. Inthout, R. Masereeuw, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8+ T cells

J. Jansen, H. Dolstra, N. Schaap, 2020, Cancer Immunology, Immunotherapy.

Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.

M. Kester, J. Jansen, G. Huls, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT

M. Labopin, H. Sengeløv, D. Blaise, 2019, Bone Marrow Transplantation.

Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study.

M. Labopin, I. Yakoub-Agha, A. Nagler, 2018, International journal of radiation oncology, biology, physics.

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

N. Kröger, M. Robin, I. Yakoub-Agha, 2021, Leukemia.

Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy

M. Kester, J. Jansen, L. Gattinoni, 2018, Oncoimmunology.

The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs

H. Lokhorst, T. Mutis, H. Dolstra, 2015, Bone Marrow Transplantation.

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

S. Verstovsek, R. Mesa, M. Talpaz, 2020, American journal of hematology.

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.

H. Putter, H. Deeg, H. Einsele, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses

A. Cambi, M. Heemskerk, J. Jansen, 2016, The Journal of Immunology.

Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation.

M. Kester, J. Falkenburg, J. Jansen, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs

H. Dolstra, K. Broen, H. Fredrix, 2012, Bone Marrow Transplantation.

The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells.

T. Radstake, J. Spanholtz, H. Dolstra, 2014, Stem cells and development.

siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8+ T cells in NOD/SCID/IL2Rg(null) mice

H. Dolstra, R. van der Voort, H. Fredrix, 2015, Cancer Immunology, Immunotherapy.

Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation

S. Milstein, T. Novobrantseva, Hila Epstein-Barash, 2013, Cancer Immunology, Immunotherapy.

Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivo

M. Kester, J. Jansen, H. Dolstra, 2017, Oncoimmunology.

Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients

R. Raymakers, F. Preijers, T. Witte, 2013, Cancer Immunology, Immunotherapy.

B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8+ T Cells in Patients After Allogeneic Stem Cell Transplantation

D. Olive, A. Korman, H. Dolstra, 2012, The Journal of Immunology.

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

Z. Shun, R. Mesa, M. Talpaz, 2017, The Lancet. Haematology.

Management of myelofibrosis after ruxolitinib failure

R. Mesa, C. Harrison, N. Schaap, 2020, Annals of Hematology.

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.

N. Kröger, S. Iacobelli, I. Yakoub-Agha, 2021, Clinical lymphoma, myeloma & leukemia.

Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion

J. Jansen, R. Raymakers, T. Witte, 2007, Bone Marrow Transplantation.

Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings

N. Kröger, M. Robin, J. Finke, 2013, Leukemia.

Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.

H. Dombret, M. Labopin, M. Mohty, 2014, European journal of cancer.

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.

W. Wiktor-Jedrzejczak, N. Kröger, S. Iacobelli, 2018, Biology of Blood and Marrow Transplantation.

A trispecific killer engager molecule against CLEC12A effectively induces NK cell mediated killing of AML cells

Jeffrey S. Miller, B. Blazar, D. Vallera, 2020, Leukemia.

Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

W. Wiktor-Jedrzejczak, N. Kröger, S. Iacobelli, 2017, Haematologica.

Relatively favorable outcome after allogeneic stem cell transplantation for BCR‐ABL1‐positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT)

J. Esteve, M. Labopin, I. Yakoub-Agha, 2018, American journal of hematology.

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia

J. Esteve, N. Kröger, C. Craddock, 2022, Cancer.

Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas

P. Dreger, A. Shimoni, A. Sureda, 2017, Journal of clinical apheresis.

Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.

J. Donnelly, N. Blijlevens, A. D. de Haan, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

'Blind' transfusion of blood products in exsanguinating trauma patients.

P. Kamphuisen, L. Geeraedts, J. Frölke, 2007, Resuscitation.

IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells

J. Safrit, P. Friedl, J. Jansen, 2020, Cancer Immunology, Immunotherapy.

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts

S. Verstovsek, R. Mesa, M. Talpaz, 2022, British journal of haematology.

Ruxolitinib in Myelofibrosis and Baseline Thrombocytopenia in Real Life: Results in Dutch Patients and Review of the Literature.

R. Raymakers, H. Koene, S. Zweegman, 2019, Clinical lymphoma, myeloma & leukemia.

siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.

T. D. de Witte, H. Dolstra, R. van der Voort, 2010, Blood.

Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party

F. Baron, M. Labopin, A. Nagler, 2020, Bone Marrow Transplantation.

CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice

J. Jansen, P. Ottevanger, H. Dolstra, 2021, Oncoimmunology.

Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT

M. Labopin, D. Blaise, M. Mohty, 2014, Bone Marrow Transplantation.

NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation

J. Jansen, T. Feuth, J. Donnelly, 2009, Bone Marrow Transplantation.

PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.

A. Korman, M. Kester, M. Quigley, 2011, Cancer research.

PD-1 signaling impairs MiHA-specific CD8+ T cells

Kester, A. Korman, Robbert, 2011 .

PD-1 / PD-L 1 interactions contribute to functional T cell impairment in patients that relapse with cancer after allogeneic stem cell transplantation

Kester, A. Korman, Robbert, 2011 .

Microenvironment and Immunology PD-1 / PD-L 1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation

A. Korman, M. Kester, M. Quigley, 2011 .

Thiotepa‐based versus total body irradiation‐based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantati

M. Labopin, A. Nagler, M. Mohty, 2016, European journal of haematology.

Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.

P. Bartolomeo, M. Robin, I. Yakoub-Agha, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group–an observational analysis by the Acute Leukemia Working Party of the EBMT

C. Craddock, M. Labopin, P. Chevallier, 2015, Bone Marrow Transplantation.

Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study

J. Esteve, M. Labopin, P. Chevallier, 2019, Clinical hematology international.

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

J. Johansson, N. Kröger, C. Craddock, 2017, British journal of haematology.

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.

M. Kersten, P. Sonneveld, B. van der Holt, 2012, Blood.

Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.

R. Raymakers, T. D. de Witte, H. Dolstra, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party.

N. Kröger, I. Yakoub-Agha, A. Nagler, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity

J. Jansen, E. Lion, H. Dolstra, 2020, Bone Marrow Transplantation.

Immune checkpoint molecules in acute myeloid leukaemia: managing the double‐edged sword

H. Dolstra, N. Schaap, W. Hobo, 2018, British journal of haematology.

Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation.

M. Kester, J. Jansen, H. Dolstra, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2

L. Arenillas, M. Fleming, D. Swinkels, 2018, Haematologica.

The phenotypic spectrum of germline YARS2 variants: from isolated sideroblastic anemia to mitochondrial myopathy, lactic acidosis and sideroblastic anemia 2

L. Arenillas, M. Fleming, D. Swinkels, 2018, Haematologica.

Intestinal Damage Determines the Inflammatory Response and Early Complications in Patients Receiving Conditioning for a Stem Cell Transplantation

T. Feuth, J. Donnelly, N. Blijlevens, 2010, PloS one.

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia

J. Esteve, F. Baron, M. Labopin, 2021, Bone Marrow Transplantation.

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT

J. Esteve, F. Baron, M. Labopin, 2018, British journal of haematology.

Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

J. Esteve, M. Labopin, I. Yakoub-Agha, 2015, Journal of Hematology & Oncology.

Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival

R. Raymakers, H. Dolstra, A. Schattenberg, 2007, Bone Marrow Transplantation.

Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia

N. Kröger, M. Robin, I. Yakoub-Agha, 2021, Frontiers in Immunology.

Immunotherapeutic approaches to treat multiple myeloma

H. Dolstra, N. Schaap, M. Roeven, 2014, Human vaccines & immunotherapeutics.

Exploratory Study of Predicted Indirectly ReCognizable HLA Epitopes in Mismatched Hematopoietic Cell Transplantations

B. van der Holt, J. Calis, J. Cornelissen, 2019, Front. Immunol..

Centre characteristics and procedure‐related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)

H. Putter, J. Delgado, N. Kröger, 2017, British journal of haematology.

Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study)

J. Jansen, L. Massuger, R. Bekkers, 2019, Medicine.

Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse

M. Labopin, A. Nagler, M. Mohty, 2018, JAMA oncology.

Concurrent Detection of Circulating Minor Histocompatibility Antigen-Specific CD8+ T Cells in SCT Recipients by Combinatorial Encoding MHC Multimers

A. Brickner, H. Dolstra, K. Broen, 2011, PloS one.

A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma

M. Kersten, M. Kester, I. Slaper-Cortenbach, 2017, Bone Marrow Transplantation.

Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation

W. Wiktor-Jedrzejczak, T. Witte, G. Gurman, 2013, Bone Marrow Transplantation.

Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

S. Montoto, P. Dreger, J. Passweg, 2019, Bone Marrow Transplantation.

LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application

M. Kester, M. Griffioen, C. V. van Bergen, 2015, Haematologica.

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

S. Montoto, S. Iacobelli, J. Sierra, 2022, Journal of clinical medicine.

Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT

N. Kröger, S. Iacobelli, M. Robin, 2014, Haematologica.

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

N. Kröger, S. Iacobelli, N. Russell, 2019, Bone Marrow Transplantation.

Tandem autologous stem cell transplantation improves outcome in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of EBMT.

N. Kröger, V. Pavone, I. Yakoub-Agha, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

H. Einsele, R. Fanin, N. Kröger, 2016, Leukemia.

F. Baron, M. Labopin, A. Nagler, 2019, Bone Marrow Transplantation.

Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT

J. Esteve, N. Kröger, M. Labopin, 2021, Bone Marrow Transplantation.

CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission

M. Labopin, P. Chevallier, I. Yakoub-Agha, 2022, HemaSphere.

Melphalan 140 mg/m2 or 200 mg/m2 for autologous trasnplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma

Christof, W. Wiktor-Jedrzejczak, N. Kröger, 2022 .

Prognostic impact of Epstein-Barr virus serostatus in patients with nonmalignant hematological disorders undergoing allogeneic hematopoietic cell transplantation: the study of Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation

P. Chevallier, I. Yakoub-Agha, J. Snowden, 2020, Acta Haematologica Polonica.

Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT

S. Montoto, N. Kröger, P. Chevallier, 2019, Bone Marrow Transplantation.

Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK‐NUP214 shows a favourable outcome when performed in first complete remission

J. Esteve, J. Sierra, M. Labopin, 2020, British journal of haematology.

Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses

M. Kester, M. Heemskerk, J. Borst, 2021, Cancer Immunology, Immunotherapy.

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

S. Verstovsek, R. Mesa, M. Talpaz, 2021, HemaSphere.

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial

S. Verstovsek, R. Mesa, M. Talpaz, 2021, HemaSphere.

Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor—A multicenter analysis

R. Oberbauer, R. Ravanan, R. Gaston, 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts

S. Verstovsek, T. Gerike, R. Mesa, 2019, Clinical Lymphoma, Myeloma & Leukemia.

S. Verstovsek, R. Mesa, M. Talpaz, 2019, Blood.

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study

S. Verstovsek, T. Gerike, R. Mesa, 2019, Clinical Lymphoma Myeloma and Leukemia.

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

A. Korman, J. Jansen, L. Massuger, 2020, Oncoimmunology.

Double Umbilical Cord Blood Transplantation in High-Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance

B. van der Holt, C. Lamers, C. V. van Bergen, 2019, HemaSphere.

Efficient Nontoxic Delivery of PD-L1 and PD-L2 siRNA Into Dendritic Cell Vaccines Using the Cationic Lipid SAINT-18

M. Ruiters, H. Dolstra, R. van der Voort, 2015, Journal of immunotherapy.

Autologous HSCT for Ph-Positive Adult Acute Lymphoblastic Leukemia: A Curative Option in the Era of Tyrosine Kinase Inhibitors? an Analysis From the Acute Leukemia Working Party of the EBMT

M. Labopin, M. Mohty, G. Socié, 2012 .

Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival

M. Kersten, P. Sonneveld, B. van der Holt, 2015, Haematologica.

Polymorphisms in CCR6 are associated with chronic graft-versus-host disease and invasive fungal disease in matched-related hematopoietic stem cell transplantation.

T. Feuth, H. Dolstra, K. Broen, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

H. Einsele, N. Kröger, I. Yakoub-Agha, 2021, Bone Marrow Transplantation.

PV-0042: Fractionated-TBI schedules prior to allograft: Study from the Acute Leukemia Working Party (EBMT)

M. Labopin, I. Yakoub-Agha, A. Nagler, 2017 .

An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

S. Iacobelli, P. Chevallier, I. Yakoub-Agha, 2023, Bone Marrow Transplantation.

Invasive Fungal Disease in Patients with Myeloid Malignancies: A Retrospective Cohort Study of a Diagnostic-Driven Care Pathway Withholding Mould-Active Prophylaxis

C. Schaefer-Prokop, S. Schalekamp, E. D. de Kort, 2022, Journal of fungi.

Allogeneic Stem Cell Transplantation in Patients >40 Years of Age With Acute Lymphoblastic Leukemia: Reduced Intensity Versus Myeloablative Conditioning.

B. van der Holt, J. Cornelissen, A. Dinmohamed, 2023, Transplantation.

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT.

J. Bourhis, I. Yakoub-Agha, D. Mclornan, 2023, Bone marrow transplantation.